Gout - Pipeline Insight, 2025
Description
DelveInsight’s, “Gout - Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gout: Overview
Gout is a form of inflammatory arthritis characterized by sudden, severe attacks of pain, redness, and tenderness in the joints, often affecting the big toe. It results from the accumulation of urate crystals, which form when there are high levels of uric acid in the blood. Uric acid is a waste product produced during the breakdown of purines, substances naturally found in certain foods and cells. Normally, uric acid dissolves in the blood and is excreted by the kidneys, but when the body produces too much or the kidneys fail to eliminate enough, uric acid levels rise, leading to the formation of sharp, needle-like crystals in joints and surrounding tissues.
Gout typically occurs in four stages: asymptomatic hyperuricemia, acute gout, intercritical gout (the symptom-free periods between attacks), and chronic gout. Acute gout is marked by intense joint pain, swelling, and redness, usually in one joint at a time. The most commonly affected joint is the big toe, although other joints such as the ankles, knees, elbows, wrists, and fingers can also be involved. The attacks often occur suddenly, often at night, and can last from a few days to a couple of weeks.
Risk factors for gout include genetic predisposition, diet, obesity, certain medications, and medical conditions like high blood pressure, diabetes, and kidney disease. Alcohol consumption, especially beer and sugary drinks, as well as foods rich in purines, such as red meat and seafood, can increase uric acid levels and trigger gout attacks. Men are more likely to develop gout than women, but the risk for women increases after menopause due to hormonal changes.
Management of gout involves both short-term treatment to alleviate symptoms and long-term strategies to prevent future attacks and complications. Acute attacks are usually treated with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids to reduce pain and inflammation. Long-term management focuses on lowering uric acid levels through lifestyle changes and medications like allopurinol or febuxostat. These medications help prevent the formation of urate crystals and decrease the frequency of gout attacks. Dietary modifications, weight management, and reduced alcohol consumption are essential components of long-term gout management.
If left untreated, gout can progress to chronic gout, leading to joint damage, persistent pain, and the development of tophi—large, painful deposits of urate crystals under the skin. Chronic gout may also increase the risk of kidney stones and other complications. However, with early diagnosis, appropriate treatment, and lifestyle changes, gout can be effectively managed, minimizing its impact on quality of life..
""Gout - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gout Emerging Drugs
Further product details are provided in the report……..
Gout: Therapeutic Assessment
This segment of the report provides insights about the different Gout drugs segregated based on following parameters that define the scope of the report, such as:
Gout: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.
Gout Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Gout: Overview
Gout is a form of inflammatory arthritis characterized by sudden, severe attacks of pain, redness, and tenderness in the joints, often affecting the big toe. It results from the accumulation of urate crystals, which form when there are high levels of uric acid in the blood. Uric acid is a waste product produced during the breakdown of purines, substances naturally found in certain foods and cells. Normally, uric acid dissolves in the blood and is excreted by the kidneys, but when the body produces too much or the kidneys fail to eliminate enough, uric acid levels rise, leading to the formation of sharp, needle-like crystals in joints and surrounding tissues.
Gout typically occurs in four stages: asymptomatic hyperuricemia, acute gout, intercritical gout (the symptom-free periods between attacks), and chronic gout. Acute gout is marked by intense joint pain, swelling, and redness, usually in one joint at a time. The most commonly affected joint is the big toe, although other joints such as the ankles, knees, elbows, wrists, and fingers can also be involved. The attacks often occur suddenly, often at night, and can last from a few days to a couple of weeks.
Risk factors for gout include genetic predisposition, diet, obesity, certain medications, and medical conditions like high blood pressure, diabetes, and kidney disease. Alcohol consumption, especially beer and sugary drinks, as well as foods rich in purines, such as red meat and seafood, can increase uric acid levels and trigger gout attacks. Men are more likely to develop gout than women, but the risk for women increases after menopause due to hormonal changes.
Management of gout involves both short-term treatment to alleviate symptoms and long-term strategies to prevent future attacks and complications. Acute attacks are usually treated with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids to reduce pain and inflammation. Long-term management focuses on lowering uric acid levels through lifestyle changes and medications like allopurinol or febuxostat. These medications help prevent the formation of urate crystals and decrease the frequency of gout attacks. Dietary modifications, weight management, and reduced alcohol consumption are essential components of long-term gout management.
If left untreated, gout can progress to chronic gout, leading to joint damage, persistent pain, and the development of tophi—large, painful deposits of urate crystals under the skin. Chronic gout may also increase the risk of kidney stones and other complications. However, with early diagnosis, appropriate treatment, and lifestyle changes, gout can be effectively managed, minimizing its impact on quality of life..
""Gout - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gout pipeline landscape is provided which includes the disease overview and Gout treatment guidelines. The assessment part of the report embraces, in depth Gout commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gout collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve Gout.
This segment of the Gout report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gout Emerging Drugs
- LC350189: LG Chem
- SAP-001: Shanton Pharma
- D-0120: InventisBio
- ABP-745: Jiangsu Atom Bioscience and Pharmaceutical
Further product details are provided in the report……..
Gout: Therapeutic Assessment
This segment of the report provides insights about the different Gout drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gout
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Protein
- Small interfering RNA
- Small molecule
- Product Type
Gout: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gout therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gout drugs.
Gout Report Insights
- Gout Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gout drugs?
- How many Gout drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gout?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gout therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gout and their status?
- What are the key designations that have been granted to the emerging drugs?
- Jiangsu Atom Bioscience and Pharmaceutical
- LG Chem
- Shanton Pharma
- TWi Biotechnology
- Olatec Therapeutics
- JW Pharmaceutical
- Revive Therapeutics
- Hinova pharmaceuticals
- Arthrosi Therapeutics
- Dyve Biosciences
- Jiangsu Atom Bioscience and Pharmaceutical
- Swedish Orphan Biovitrum
- Allen Pharmaceuticals
- Teijin Pharma
- AstraZeneca
- R-Pharm
- InventisBio
- Sinovent
- Shenyang Sunshine Pharmaceutical
- ABP-745
- SHR4640
- SEL-212
- LC350189
- SAP-001
- AC-201
- Dapansutrile
- URC-102
- Bucillamine
- HP501
- AR882
- DYV700
- ABP-671
- Anakinra
- ALLN-346
- TMX-049
- Verinurad
- RPH-104
- D-0120
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Gout: Overview
- Causes
- Signs and Symptoms
- Pathophysiology
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Gout– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- LC350189: LG Chem
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- SAP-001: Shanton Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ABP-745: Jiangsu Atom Bioscience and Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Gout Key Companies
- Gout Key Products
- Gout- Unmet Needs
- Gout- Market Drivers and Barriers
- Gout- Future Perspectives and Conclusion
- Gout Analyst Views
- Gout Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
